top of page

FAQs

Here's answers to some of the most commonly asked questions. Please get in touch if the information you are looking for is not located below.

  • What is the Bredesen ReCODE Protocol™?
    ReCODE is a comprehensive and personalised multi-therapeutic approach for reversing symptoms of cognitive decline and optimising brain health using nutrition, exercise (physical and mental), sleep, stress management, detoxification, supplements and hormones to address the risk factors that drive the symptoms.
  • Who would benefit from the ReCODE Protocol™?
    The Bredesen Protocol® is for anyone who: · Wants to prevent cognitive decline · Has a family history of any cognitive issue including Alzheimer’s disease (AD) · Is suffering from brain fog and fatigue · Has noticed subjective cognitive impairment (SCI) · Has been diagnosed with mild cognitive impairment (MCI) or Alzheimer’s disease (AD) · Wants to improve their concentration and focus and become more productive · Wants to develop healthy living habits
  • How long will it take to notice results from the ReCODE Protocol™?
    This is dependent on the degree of cognitive decline and the level of commitment to the protocol and improving eating and lifestyle habits. A 2021 study shows that a multi-factorial, comprehensive and personalised therapeutic program, designed to mitigate AD risk factors, can improve risk factor scores and stabilise or reverse the decline in cognitive function over 3-9 months. Dr Bredesen’s 2018 trial using the protocol showed reversal of early-stage dementia incrementally over 12 months.
  • Does the ReCODE Protocol™ cure Alzheimer’s?
    A complete cure has not yet been found for AD, but a slowing and reversing of the condition has been achieved using the Bredesen ReCODE Protocol. If all the core strategies are implemented and followed simultaneously, and the program continued, the improvements from these strategies are typically sustained, thus offering a major advantage over mono-therapeutics. If the symptoms and potential causes for AD are identified at the early pre-symptomatic stages, the implementation of ReCODE allows for correcting these contributors and preserving cognitive health. (Rao 2021)
bottom of page